An index of clinical-stage biotech companies developing psychedelic-assisted therapies for depression, PTSD, and addiction, a nascent sector that could disrupt the $500B mental-health drug market.
An index of clinical-stage biotech companies developing psychedelic-assisted therapies for depression, PTSD, and addiction, a nascent sector that could disrupt the $500B mental-health drug market.
Made 30 Apr 2026. Refreshed every 6 months.
Discussion
What stocks are in Psychedelic Medicine Breakthrough Index?
It holds 10 companies. The largest are COMPASS Pathways (CMPS), MindMed (MNMD), atai Life Sciences (ATAI), Cybin (CYBN) and LAVA Therapeutics (LVTX), followed by NUMI, TRYP, MNTV, DELI and MEDS. Most of the money is in healthcare.
How has Psychedelic Medicine Breakthrough Index performed?
+21.8% over the past year against +29.4% for the S&P 500, −57.8% over five years in the backtest. Results before the creation date are simulated from real past prices and leave out fees and taxes. Past performance is not a guide to the future.
How is Psychedelic Medicine Breakthrough Index weighted?
Every company gets the same share. The biggest holding is COMPASS Pathways (CMPS) at 14.0%.
Can I invest in Psychedelic Medicine Breakthrough Index?
It is not a fund you can buy. It is a list of shares you can buy yourself at your broker, and Arithmos shows you how for more than 40 brokers, or creates it as a Trading 212 pie. Arithmos is a research tool, not investment advice.
Backtests, risk ratios, how it was built and more are in Complex mode.
More detail
What’s inside
10 companies. The biggest is COMPASS Pathways at 14%.
Percentages are target weights at the last rebalance.
Weighting: equalRebalance: semiannual
Company pages
Each company’s price history, and the other portfolios that hold it.
Results before a portfolio’s creation date are simulated from real historical prices and don’t include fees, taxes or trading costs. How we calculate performance. Investing puts your money at risk: you can lose some or all of it. Nothing here is investment advice.
Want the short version? Simple mode shows just the essentials.